title: Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients.
abstract: OBJECTIVE
  High protein diets have been shown to improve hepatic steatosis in rodent models and in high-fat fed humans. We therefore evaluated the effects of a protein supplementation on intrahepatocellular lipids (IHCL), and fasting plasma triglycerides in obese non diabetic women.
  
  
  METHODS
  Eleven obese women received a 60 g/day whey protein supplement (WPS) for 4-weeks, while otherwise nourished on a spontaneous diet, IHCL concentrations, visceral body fat, total liver volume (MR), fasting total-triglyceride and cholesterol concentrations, glucose tolerance (standard 75 g OGTT), insulin sensitivity (HOMA IS index), creatinine clearance, blood pressure and body composition (bio-impedance analysis) were assessed before and after 4-week WPS.
  
  
  RESULTS
  IHCL were positively correlated with visceral fat and total liver volume at inclusion. WPS decreased significantly IHCL by 20.8 ± 7.7%, fasting total TG by 15 ± 6.9%, and total cholesterol by 7.3 ± 2.7%. WPS slightly increased fat free mass from 54.8 ± 2.2 kg to 56.7 ± 2.5 kg, p = 0.005). Visceral fat, total liver volume, glucose tolerance, creatinine clearance and insulin sensitivity were not changed.
  
  
  CONCLUSIONS
  WPS improves hepatic steatosis and plasma lipid profiles in obese non diabetic patients, without adverse effects on glucose tolerance or creatinine clearance.
  
  
  BACKGROUND
  NCT00870077, ClinicalTrials.gov.
authors.affiliation: Department of Physiology, University of Lausanne, 7, rue du Bugnon, 1005 Lausanne, Switzerland. murielle.bortolotti@unil.ch
authors.forename: Murielle
authors.initials: M
authors.lastname: Bortolotti
authors.forename: Elena
authors.initials: E
authors.lastname: Maiolo
authors.forename: Mattia
authors.initials: M
authors.lastname: Corazza
authors.forename: Eveline
authors.initials: E
authors.lastname: Van Dijke
authors.forename: Philippe
authors.initials: P
authors.lastname: Schneiter
authors.forename: Andreas
authors.initials: A
authors.lastname: Boss
authors.forename: Guillaume
authors.initials: G
authors.lastname: Carrel
authors.forename: Vittorio
authors.initials: V
authors.lastname: Giusti
authors.forename: Kim-Anne
authors.initials: KA
authors.lastname: Lê
authors.forename: Daniel Guae
authors.initials: DG
authors.lastname: Quo Chong
authors.forename: Tania
authors.initials: T
authors.lastname: Buehler
authors.forename: Roland
authors.initials: R
authors.lastname: Kreis
authors.forename: Chris
authors.initials: C
authors.lastname: Boesch
authors.forename: Luc
authors.initials: L
authors.lastname: Tappy
mesh_terms: D000328:Adult; D000596:Amino Acids / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects; D002784:Cholesterol / Q000097:blood*; D002857:Chromium; D003404:Creatinine / Q000378:metabolism; D004032:Diet; D019587:Dietary Supplements; D005215:Fasting; D005234:Fatty Liver / Q000188:drug therapy; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008894:Milk Proteins / Q000494:pharmacology*; D009539:Nicotinic Acids; D009765:Obesity / Q000188:drug therapy*; D009929:Organ Size; D014280:Triglycerides / Q000097:blood*; D000067816:Whey Proteins
chemical_list: D000596:Amino Acids; D001786:Blood Glucose; D007328:Insulin; D008894:Milk Proteins; D009539:Nicotinic Acids; D014280:Triglycerides; D000067816:Whey Proteins; C015240:glucose tolerance factor; D002857:Chromium; D002784:Cholesterol; D003404:Creatinine